Lunai Bioworks Inc. (LNAI)
| Market Cap | 9.08M -83.6% |
| Revenue (ttm) | 20,942 |
| Net Income | -128.28M |
| EPS | -5.78 |
| Shares Out | 36.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 444,486 |
| Open | 0.2620 |
| Previous Close | 0.2585 |
| Day's Range | 0.2502 - 0.2620 |
| 52-Week Range | 0.1513 - 4.4960 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About LNAI
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its rec... [Read more]
Financial Performance
Financial StatementsNews
Lunai Bioworks Quarterly report: Q3 2026
Lunai Bioworks has published its Q3 2026 quarterly earnings report on May 15, 2026.
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock
WASHINGTON, D.C. , May 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- On Monday, May 11, 2026, national law firms Dickinson Wright and Fox Rothschild joined forces to file a lawsuit on behalf of their firms'...
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applications SACRAMENTO, Calif., May 4, 2026 /PRNewswire...
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Collaboration converts patient-led data into trial-ready cohorts to support drug development, commercial partnerships, and revenue-generating opportunities. Initial programs underway to integrate rare...
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on April 13, 2026, providing details for shareholder voting and corporate governance matters.
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
Advancing AI-enabled chemical threat detection and dual-use biodefense technologies through initial commercial deployment SACRAMENTO, Calif., April 7, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ...
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
Lunai Bioworks acquires BBB delivery platform in Alzheimer’s for $20M
Lunai Bioworks (LNAI) has executed a binding $20M strategic transaction to acquire blood-brain barrier, or BBB, delivery technology and central nervous system, or CNS, Alzheimer’s drug assets from the...
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
SACRAMENTO, Calif., March 26, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) ...
Lunai Bioworks announces formation of Pathfinder Consortium
Lunai Bioworks (LNAI) announced the formation of a national consortium designed to accelerate the discovery and development of chemical countermeasures for emerging battlefield and terrorism threats. ...
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
AI platform integrates academic and defense research to accelerate rapid antidote discovery and federal stockpiling for emerging chemical threats. SACRAMENTO, Calif.
Why Is Lunai Bioworks Stock (LNAI) Rallying Today?
Lunai Bioworks stock experienced strong gains on Tuesday despite a lack of news from the company.
Lunai Bioworks granted U.S. patent for AI drug discovery system
Lunai Bioworks (LNAI) announced the issuance of a U.S. patent titled “Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions.” The newly issued patent protects the foundatio...
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
Foundational Patent Strengthens AI Moat Across Multimodal Data Standardization, Disease Stratification and Gene Mapping SACRAMENTO, Calif., Feb. 19, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: ...
Lunai Bioworks Quarterly report: Q2 2026
Lunai Bioworks has published its Q2 2026 quarterly earnings report on February 17, 2026.
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
SACRAMENTO, Calif., Feb. 13, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute.
Lunai Bioworks CEO says established three ‘scalable revenue generating engines’
In a letter to shareholders, CEO David Weinstein said, in part, “We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving…
Lunai Bioworks announces oncology collaboration with a clinical-stage partner
Lunai Bioworks (LNAI) announced the launch of a new oncology collaboration with a clinical-stage partner to analyze data from a randomized Phase 2 metastatic colorectal cancer trial. The objective is…
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data
AI-driven analysis of Phase 2 survival and progression data aims to identify high-benefit patient subgroups and optimize future registrational trial strategy SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswi...
Lunai Bioworks Slides: Investor presentation
Lunai Bioworks has posted slides in relation to its latest quarterly earnings report, which was published on February 5, 2026.
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
Transformer-based biosecurity layer embeds directly into foundation models, using Lunai's proprietary toxicology and in-vivo datasets to detect and prevent creation of previously unknown threat agents...
Lunai Bioworks expands AI program into commercial AUD drug discovery
Lunai Bioworks (LNAI) completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol w...